SION Sionna Therapeutics, Inc.
Distress ·
Sionna Therapeutics said it will cut about 46% of its workforce, expects about $6.4 million in restructuring charges, and expects its cash to last into the second half of 2029. The cuts follow a missed key endpoint for SION-719 in a Phase 2a trial.
Sionna Therapeutics signed a sales agreement with Leerink Partners LLC on March 2, 2026 for up to $250,000,000 of common stock sold at the market. Leerink's commission is up to 3.0% of the gross sales price per share.
The offering totals $190,588,194, and the stock is approved to list on Nasdaq under SION. Proceeds to the company are $177,247,020 before expenses.
Sionna Therapeutics filed a preliminary S-1 on January 17, 2025 for an IPO of common stock on the Nasdaq Global Market under SION. The filing leaves the share count, price range and net proceeds blank, and lists Goldman Sachs & Co. LLC, TD Cowen, Stifel and Guggenheim Securities as underwriters without marking a lead.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $60.3 million | $57.3 million |
| Net income (loss) | -$75.3 million | -$61.7 million |
| Cash from operations | -$66.3 million | -$52.8 million |
| Cash and equivalents | $58.5 million | $37.8 million |
Our latest story on this, dated Feb 7, 2025: "Sionna Therapeutics prices IPO of 10,588,233 shares at $18.00". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 2, 2026: "Sionna Therapeutics files automatic shelf with $250,000,000 ATM sales agreement". The story links the filing or release it is based on. Read the story.
Sionna Therapeutics, Inc. trades under the ticker SION on NASDAQ.
Sionna Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Sionna Therapeutics, Inc. is 2036042. Its filings are on SEC EDGAR.
45,212,399 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Sionna Therapeutics, Inc. under United States.
Our directory classifies Sionna Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Sionna Therapeutics, Inc. is US8294011080.
aibio.space lists Sionna Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Sionna Therapeutics, Inc. reported a net loss of $75.3 million for the fiscal year ended Dec 31, 2025, and used $66.3 million of cash in operations, per its annual report to the SEC.
$60.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
$63.3 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Sionna Therapeutics, dated Sep 14, 2026: "Sionna Therapeutics cuts about 46% of workforce, sees cash into second half of 2029". Sionna Therapeutics said it will cut about 46% of its workforce, expects about $6.4 million in restructuring charges, and expects its cash to last into the second half of 2029. The cuts follow a missed key endpoint for SION-719 in a Phase 2a trial. Source.
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,8.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. Source
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio